The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research. This federated network uses Lifebit’s Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in… Read More
The Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. To achieve this, CZI will collaborate with partners 10x Genomics, Ultima Genomics, and a group of… Read More
Standardisation is critical to extracting the full potential of analytical data – in facilitating data-driven science and AI/ML-powered innovation. A new whitepaper entitled ‘Standardization of Analytical Data: Best Practices‘ is now available to download for free. The whitepaper will help you: Review currently available standard formats Understand the pros… Read More
Standardisation is critical to extracting the full potential of analytical data – in facilitating data-driven science and AI/ML-powered innovation. This whitepaper will help you: Review currently available standard formats Understand the pros and cons of open and proprietary formats Ensure data is adequately prepared for scientists and AI/ML applications… Read More
Pharma R&D is transitioning toward an AI/data driven model of drug discovery, and great progress has been made in the last 20 years. To fully exploit the potential of this technology we must think holistically about how it is integrated into R&D. Fit-for-purpose data is essential, as are models that… Read More
David Gosalvez, Head of Product Strategy and Zev Wisotsky, Senior Principle Marketing Manager for Biologics at Revvity Signals, highlight how three powerful AI and ML capabilities are driving lab innovation: enhancing data accessibility, enabling intelligent chemical reaction recommendations, and automating complex cellular imaging. Enhancing data accessibility with generative AI A… Read More
This article is sponsored by CAS. Jacob Al-Saleem, PhD, Senior Data Scientist at CAS, explains why it is important to take a data-first approach when building predictive models for drug discovery. Since the early 2000s, big tech companies have been compiling and analysing user… Read More
Mark Auty, lab automation and standardisation scientist at Unilever discusses why everyone has to be aware of cyber security threats. I’m not a cyber guy, I started working as a research chemist 25 years ago. Everyone had paper lab notebooks and only managers and a few instruments had computers. Windows… Read More
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The most impactful drug discovery news this week is all linked with scientific research… Read More
News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant… Read More
